Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fate Therapeutics
Fate Therapeutics
Genocea Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Merck Sharp & Dohme LLC
Stanford University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)